Bristol-Myers Squibb Co. vs Johnson & Johnson
BMY vs JNJ — side-by-side comparison from reported financials. BMY leads 5, JNJ leads 6 of 11 comparable metrics.
Bristol-Myers Squibb Co.
BMY · Healthcare
$59.14-0.75%Solid
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | BMY | JNJ |
|---|---|---|
| Price | $59.14 | $261.79 |
| Market cap | $121B | $631B |
| Revenue (TTM) | $49.2B | $97.9B |
| Revenue growth | +1.4% | +5.6% |
| Net margin | 18.9% | 21.5% |
| Free cash flow | $11.4B | $22.2B |
| Net cash (debt) | ($34.4B) | ($27.8B) |
| 1-year price return | +32.4% | +37.0% |
| P/E | 13.0 | 29.9 |
| P/E vs own history (cheap-side %) | 90% | 16% |
| Dividend yield | 6.28% | 2.00% |
| Return on equity | 47% | 26% |
| Altman Z-score | 2.16 | — |
| CV checks passed | 11 of 11 | 10 of 11 |
| Employees | 32,500 | 140,800 |
Full résumé-style profiles: BMY CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.